Payment overview · 2025
General Payments
$1,278.45
57 reported records · 9 companies
Healthcare provider profile · identity verified
Meredith D Stempel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TANNERSVILLE, PA · NPI 1992800700
Verified facts
What the public records show
CMS Open Payments records show Meredith D Stempel, MD received $1,278.45 in general payments during 2025 across 57 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Jardiance, Ozempic, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Zenpep by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $374.62 | 29.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $283.55 | 22.2% | 19 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $273.64 | 21.4% | 17 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $157.61 | 12.3% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $91.99 | 7.2% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.49 | 3.6% | 2 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $16.87 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.87 | 1.3% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $16.81 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,278.45 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $364.23 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $283.55 | 19 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $283.55 | 19 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $261.19 | 16 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $157.61 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.19 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.49 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.33 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $28.80 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $16.81 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $12.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $10.39 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 287 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 128 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 117 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 81 | 25 |
| Lisinopril | Lisinopril | 80 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 77 | 23 |
| Metformin Hcl | Metformin Hcl | 75 | 25 |
| Losartan Potassium | Losartan Potassium | 64 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 56 | 19 |
| Zenpep | Lipase/Protease/Amylase | 55 | 15 |
| Eliquis | Apixaban | 45 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 43 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | suppressed |
| Gabapentin | Gabapentin | 27 | 12 |
| Valsartan | Valsartan | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Jardiance | Empagliflozin | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Furosemide | Furosemide | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Omeprazole | Omeprazole | 24 | suppressed |
| Potassium Chloride | Potassium Chloride | 24 | 13 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Cefdinir | Cefdinir | 20 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Prednisone | Prednisone | 19 | 13 |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 16 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Baqsimi | Glucagon | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,278.45 · 57 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CREON, Cologuard Collection Kit, FARXIGA, Hillrom - Monarch Airway Clearance System, JARDIANCE, LINZESS, LOREEV XR, NEXLETOL, Ozempic, Rybelsus, VOWST, Wegovy, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error